Trials / Completed
CompletedNCT02453711
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 957 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | semaglutide | Once-daily subcutaneous (s.c., under the skin) administration with dose escalation. |
| DRUG | liraglutide | Once-daily subcutaneous (s.c., under the skin) administration with dose escalation. |
| DRUG | placebo | Once-daily subcutaneous (s.c., under the skin) administration. |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-03-30
- Completion
- 2017-04-12
- First posted
- 2015-05-25
- Last updated
- 2020-04-17
- Results posted
- 2020-04-17
Locations
74 sites across 8 countries: United States, Australia, Belgium, Canada, Germany, Israel, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT02453711. Inclusion in this directory is not an endorsement.